With limited real-world data on the safety and efficacy of tolvaptan since its approval to treat ADPKD in 2014, investigators conducted post-marketing surveillance to evaluate the long-term safety and efficacy of the agent in...
Read MoreThis podcast is sponsored by Anelto, a leading technology platform that enables innovative healthcare solutions to keep seniors connected to healthcare providers from anywhere. Visit www.anelto.com. Guests: Todd...
Read MoreInitiating or maintaining tolvaptan therapy significantly delayed estimated glomerular filtration rate (eGFR) decline in patients with baseline eGFR of 15-24 and 25-29 ml/min per 1.73 m2, according to a study published in Kidney...
Read MoreAs the shortage of experienced and skilled physicians continues to grow nationwide, so will cases of physician burnout. There simply aren’t enough physicians and enough hours in the day to cover all the needs. After many years...
Read More
I was looking at a report the other day when something caught my attention. I wasn’t surprised to...
Read More
Autosomal dominant polycystic kidney disease (ADPKD), the most frequent hereditary renal disease...
Read More
Interview with presenter at ESC 2021 plenary talk, Prof. Stefan Anker, MD, PhD, about the full...
Read MoreA novel analysis of DAPA-HF investigated the efficacy of dapagliflozin on ventricular arrhythmia (VA), resuscitated cardiac arrest (RCA), and sudden death. The results showed a significantly reduced likelihood for the composite...
Read MoreThe GUIDE-HF trial, presented in a Hot Line Session and simultaneously published in The Lancet, showed benefits of hemodynamic-guided heart failure (HF) management with an implantable device in reducing HF hospitalization [1,2]....
Read MoreAn American trial investigated the potential of valsartan in slowing the course of disease in hypertrophic cardiomyopathy (HCM). The results showed a significantly positive influence on relative cardiac remodeling in the...
Read MoreThe randomized controlled STEP trial revealed that lowering the systolic blood pressure (SBP) to below 130 mmHg in patients over 60 years led to a 26% reduction of adverse cardiovascular (CV) events [1]. A target SBP below 130...
Read MoreEMPEROR-Preserved proved to be a landmark trial in heart failure research. It demonstrated a clinically meaningful benefit of 21% reduction in the primary composite outcome as well as positive results in secondary outcomes with...
Read MorePlease keep an eye out for an email from us! *Terms and Conditions
Read More
Location Name* Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and...
Read More
Based on prior observations, researchers evaluated the associations of overweight and obesity with...
Read MoreLocation Name* Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and...
Read More
